Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 51: EUROPA-Studie - KHK Abb. 52: EUROPA-Studie - Perindopril - Benefit Abb. 53: EUROPA-Studie - Interaktionsanalyse Aktuelles Bild - Abb. 54: EUROPA-Studie - Benefits Abb. 55: EUROPA-Studie - HOPE-Studie Abb. 56: EUROPA-Studie - HOPE-Studie Abb. 57: EUROPA-Studie - HOPE-Studie Zum letzten Bild
Abbildung 54: EUROPA-Studie - Benefits
EUROPA trial demonstrated benefit for all coronary artery disease patients including large cohort of low, but also, medium and high risk patients randomised in the previous trials (I.e. HOPE, SOLVD, SAVE, AIRE, TRACE). Prof. Kim Fox, the EUROPA chairman commented: "The results from the EUROPA trial demonstrate some of the largest benefits ever seen in the prevention of chronic disease".
 
EUROPA-Studie - Benefits
Vorheriges Bild Nächstes Bild   


Abbildung 54: EUROPA-Studie - Benefits
EUROPA trial demonstrated benefit for all coronary artery disease patients including large cohort of low, but also, medium and high risk patients randomised in the previous trials (I.e. HOPE, SOLVD, SAVE, AIRE, TRACE). Prof. Kim Fox, the EUROPA chairman commented: "The results from the EUROPA trial demonstrate some of the largest benefits ever seen in the prevention of chronic disease".
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung